WO2004110585A1 - 放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤 - Google Patents
放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤 Download PDFInfo
- Publication number
- WO2004110585A1 WO2004110585A1 PCT/JP2004/007171 JP2004007171W WO2004110585A1 WO 2004110585 A1 WO2004110585 A1 WO 2004110585A1 JP 2004007171 W JP2004007171 W JP 2004007171W WO 2004110585 A1 WO2004110585 A1 WO 2004110585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radial spherical
- supercritical fluid
- crystallized product
- crystallization
- modifier
- Prior art date
Links
- 238000002425 crystallisation Methods 0.000 title claims abstract description 53
- 230000008025 crystallization Effects 0.000 title claims abstract description 50
- 239000000843 powder Substances 0.000 title claims abstract description 16
- 238000007440 spherical crystallization Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 9
- 238000000034 method Methods 0.000 title description 20
- 239000012530 fluid Substances 0.000 claims abstract description 64
- 239000003607 modifier Substances 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 37
- 239000001569 carbon dioxide Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 13
- 229940088679 drug related substance Drugs 0.000 claims description 13
- 239000013078 crystal Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 13
- 238000012377 drug delivery Methods 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 56
- 239000002245 particle Substances 0.000 description 50
- 239000000523 sample Substances 0.000 description 44
- 239000000126 substance Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 239000012488 sample solution Substances 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
- 239000008101 lactose Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000000621 bronchi Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000001046 rapid expansion of supercritical solution Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000010887 waste solvent Substances 0.000 description 2
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229910018879 Pt—Pd Inorganic materials 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
- B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
Definitions
- the present invention relates to a radial spherical crystallized product, and more particularly, to a radial spherical crystallized product produced by a crystallization technique using a supercritical fluid and having a needle-like portion.
- the resulting radial spherical crystallization can be used as a drug delivery vehicle for transmucosal and pulmonary administration.
- a dry powder inhalant is a drug that inhales a drug substance powder and delivers it to the alveoli or bronchi at the administration site.
- the particle size of the drug substance must be 0.5 to 5 m. It is necessary.
- the drug substance is often adjusted to the above particle size by pulverization, so that it is not possible to overlook adhesion due to static electricity and cohesiveness, such as adhesion to inhalation devices and formation of secondary particles due to aggregation of particles. was a problem.
- a method of attaching a fine drug substance to a carrier has been developed for the purpose of improving the release rate from a device and preventing aggregation of particles.
- the carrier fills the device with the drug substance adhered to its surface, and when inhaling, the turbulence created by the inhalation occurs in the device, and the turbulent flow causes the carrier and the drug substance to form.
- the drug substance reaches the target site, but the carrier may be deposited in the oral cavity. Therefore, with this method, the inhalation efficiency (pulmonary coverage) is generally low at about 30%, and the remaining 70% deposited at other than the target site may cause side effects.
- the supercritical fluid is a fluid that is a fluid at a temperature and pressure higher than the critical temperature (Tc) and critical pressure (Pc).
- Tc critical temperature
- Pc critical pressure
- the fluid density changes greatly even with a small change in pressure, and the solvent can be freely controlled.
- the density of supercritical fluid is 0.1-0.9g 'dm- 3 under normal conditions.
- the most commonly used supercritical fluid is diacid carbon. The reason is that it is inexpensive, has no toxicity, does not burn, and is easy to obtain a supercritical state with a low critical temperature. You.
- the other is a gas non-dissolution (GAS) recrystallization method, in which a target solid does not dissolve in a supercritical fluid or a modified supercritical fluid, and in some cases, has a very small solubility. Useful if not available.
- GAS gas non-dissolution
- the solute of interest is dissolved in a common solvent.
- Dioxygen carbon or other supercritical fluid is introduced into the solution and the volume of the solution is rapidly expanded. As a result, the solvating power sharply decreases in a short time, creating an opportunity for crystallization of particles (see Non-Patent Document 2).
- Non-Patent Document 1 Jasco Report “Special Issue on Supercritical Technology”, JASCO, May 8, 1997
- the present invention can be applied to a carrier to which a drug substance is attached or a drug substance itself to reach a target site such as a lung or a bronchus. It is an object of the present invention to provide a fine drug substance or a fine carrier that can be advantageously used as a drug or a drug delivery vehicle.
- the present inventors have conducted intensive studies to obtain a fine drug substance and a fine carrier suitable for a dry powder inhalant, and as a result, have adjusted the conditions in the crystallization of supercritical fluid force. As a result, it has been found that a radial spherical crystallized product having a plurality of radially extending needle-like portions and having a small force can be obtained.
- a first aspect of the present invention is a radial spherical crystallization having a plurality of needle-like portions radially extended with a central force directed outward.
- the second aspect of the present invention relates to a method for introducing a supercritical fluid, which may contain a modifier, and a sample component-containing solution into a crystallization vessel through different flow paths and ejecting them into the crystallization vessel.
- a supercritical fluid which may contain a modifier
- a sample component-containing solution into a crystallization vessel through different flow paths and ejecting them into the crystallization vessel.
- a third aspect of the present invention is to guide a supercritical fluid, which may contain a modifier, and a sample component-containing solution to a crystallization vessel through different flow paths, and to eject these into the crystallization vessel.
- This is a method for producing a radial spherical crystallized product, which is brought into contact with a sphere.
- a fourth aspect of the present invention is a dry powder preparation containing, as an active ingredient, a radial spherical crystallized product produced using a pharmaceutical drug as a sample component.
- a fifth aspect of the present invention is a dry powder preparation containing, as a carrier, a radial spherical crystallization product produced using a preparation carrier as a sample component.
- This radial spherical crystallized substance is used as a drug substance for DPI when it is composed of a drug itself, and when it is a drug carrier, it is used as a DPI carrier that reaches the lungs and mucous membranes while carrying the drug. Applicable. BEST MODE FOR CARRYING OUT THE INVENTION
- the radial spherical crystallized product of the present invention is a crystallized product in which a large number of needle-like objects extend outward from the crystal center and have a substantially spherical shape (see FIGS. 1 and 2). .
- This shape can be expressed in other ways, such as a “penny-like” shape, in which the outer surface of a spherical shell is covered with long thorns, or a “coni” shape of a chestnut. It can also be called “conical algae (marimo)."
- the crystallized substance having such a shape is obtained by growing a crystal with a sample component as a nucleus in a supercritical fluid and forming a plurality of radiating needle-like sites.
- the number and shape of the "needle-shaped portions" of the radial spherical crystallized product of the present invention vary depending on crystallization conditions and the like, and the "needle-shaped” includes a rod-shaped or plate-shaped.
- the “spherical shape” in the present invention includes not only a perfect spherical shape but also a substantially spherical shape, and includes an ellipsoidal sphere and a flat sphere.
- the aerodynamic diameter of the radial spherical crystallized product (hereinafter referred to as "crystallized product”) of the present invention is about 0.1 to 20 ⁇ m. However, for example, if it is used for pulmonary administration, it should be adjusted to about 0.1-5 / zm.If it is used for local administration to the bronchi, etc., it should be adjusted to about 0.5-20 / zm. It is desirable.
- the aerodynamic diameter is a particle diameter related to the inertia of the air flow field, which is not a geometric length, and its particle size distribution is, for example, an Andersen cascade impactor, a multi-liquid impinge. It can be measured using a jar or the like, and as a simple method, it can be measured using an aerobicizer or the like.
- the bulk density of the crystallized product is about 100 mgZmL or less, and preferably 30-100 mgZmL.
- the bulk density is a value obtained by filling a container having a known volume with powder by a certain method, and dividing the mass of the powder by the volume including voids between particles. A sample is gently placed, the mass of the sample when the sample is filled with 10 mL is measured, and the value is obtained by dividing the mass by 1 OmL.
- the crystallization product of the present invention is obtained, for example, by mixing a supercritical fluid mixed with a modifier as needed and introduced into a different flow channel, and a sample component-containing solution from the flow channel into the crystallization vessel. It is manufactured by contacting when squirting.
- the "sample component” is a substance to be crystallized, It is a substance having the property of being insoluble or almost insoluble in the supercritical fluid or a mixture of the supercritical fluid and the modifier described below. This substance is not particularly limited as long as it has the above-mentioned properties, but when the radial spherical crystallized product of the present invention is used as a drug or a carrier thereof, pharmaceutically acceptable active ingredients and excipients are used. It is preferably a component or a mixture thereof.
- the prepared crystallized product can be directly used for transmucosal / pulmonary administration. Further, when a crystallized product is prepared using an excipient as a sample component, the active ingredient can be carried on the needle-like site of the crystallized product, and used for transmucosal or pulmonary administration.
- the sample component selected is preferably a substance having good biocompatibility, for example, sugar or sugar alcohol. Is lactose.
- sample component-containing solution in the present invention is a solution in which a sample component to be crystallized is dissolved or suspended, and the selected “solvent” is the type of the sample component to be crystallized. It will be decided according to. For example, when sugar or sugar alcohol is used as a sample component, water is preferable. This solvent does not need to be one kind, but may be a mixture of two or more kinds of solvents.
- the "supercritical fluid" in the production of a crystallized substance means a fluid at a pressure and temperature higher than the critical pressure (Pc) and the critical temperature (Tc).
- the pressure of the supercritical fluid is often in the range of 1.01-7.0Pc, and the temperature is often in the range of 1.01-4.0Tc.
- a substance used as a supercritical fluid is a substance which easily liquefies at a relatively low pressure and reaches a supercritical state at low pressure and low temperature.
- Such materials include carbon dioxide, nitrous sulfide, sulfur hexafluoride, xenon, ethylene, ethane, chlorotrifluoromethane and trifluoromethane, but are inexpensive, non-toxic and do not burn. That the critical temperature is low and the supercritical state is easily obtained.
- the “crystallization vessel” used in the present invention has a container in which the inside is maintained at a temperature and pressure at which a gas or liquid used as a supercritical fluid becomes a subcritical or supercritical fluid. The diffusion and crystallization of the sample components are performed.
- a "modifier” can be mixed in a supercritical fluid, if necessary.
- This modifier also called a modifier or co-solvent, has the property of mixing with the supercritical fluid to change the supercritical properties at or near the critical point.
- the modifier is not particularly limited, but when the supercritical fluid is carbon dioxide and the sample solution is water, an alcohol such as ethanol is exemplified.
- the solubility of the sample component in the mixed liquid of the supercritical fluid and the modifier is small, and the supercritical fluid or the like acts as a so-called poor solvent for the sample component.
- the shape and size of the crystallized product may be related to the amount of the modifier contained in the supercritical fluid.
- the flow rate of the modifier is increased by keeping the flow rate of the supercritical fluid constant.
- the particle diameter gradually decreases and the ethanol flow rate is about one-fourth of the carbon dioxide flow rate. If the flow rate of ethanol is further increased, needle-like sites disappear, and a normal recrystallized product (Tomahawk type) is produced (see Fig. 12). A precipitate can be obtained.
- FIG. 3 is a drawing showing an outline of an example of an apparatus used for producing a crystallized product.
- 1 is a thermostat
- 2 is a crystallization vessel
- 3 is a nozzle
- 4 is a back pressure regulator
- 5 is a sample solution feed pump
- 6 is a supercritical fluid feed pump
- 7 is a modifier solution pump
- 8 is a sample solution container
- 9 is a medium container for supercritical fluid
- 10 is a modifier solution container
- 11 is a mixing column (coil)
- 12 is a waste solvent recovery container.
- a is a sample piping
- b is a supercritical fluid piping
- c is a modifier piping
- d is a discharge piping.
- the temperature in the crystallization vessel 2 is set to a temperature at which the supercritical fluid can exist in a subcritical or supercritical state in the thermostatic oven 1. .
- the supercritical fluid is sent out into the crystallization vessel 2 and the back 'pressure' regulator 4 Is adjusted to maintain a pressure at which the supercritical fluid can exist in a subcritical or supercritical state.
- the supercritical fluid and the modifier are mixed in the mixing column 11 through the respective pipes b and c, and the mixed liquid is sent into the crystallization vessel 2.
- the flow rate of the supercritical fluid and the modifier is determined by the flow rate ratio at which the sample forms a radial spherical crystallized substance.
- the flow rate of carbon dioxide is maximized, and the ethanol flow rate is calculated as 4 Adjust to one-half.
- the solvent in which the sample components are suspended or dissolved is sent out into the crystallization vessel 2 through the sample solution pipe a, and the nozzle 3a installed in the vessel is used for the nozzle 3b.
- the mist sample solution is brought into contact with and mixed with the mixed solution of the mist and the modifier so that the sample crystallizes in the container 2.
- a V-shaped nozzle may be used as the nozzle 3 (H. Okamoto, S.
- a radiated spherical crystallized product is obtained by the method of the present invention is considered as follows. That is, the “sample component-containing solution” and the “supercritical fluid” or the “mixture of the supercritical fluid and the modifier” are introduced into the crystallization vessel 2 through different flow paths without contact outside the crystallization vessel 2. Is done. Then, immediately after entering the crystallization vessel 2, the two come into contact with each other, and the vibrating force causes the solution containing the sample component to become a fine mist and scatter (diffuse) into the crystallization container, thereby causing small particles of the sample component to be dispersed. It is thought that the nucleus becomes a nucleus and a needle-like part grows to form a spherical crystal.
- the power of the carbon dioxide pump was turned on, and the pump power was waited until the pump was cooled to 5 ° C.
- turn on the knock 'pressure' regulator set the pressure and temperature, open the carbon dioxide flow path valve and the main valve of the carbon dioxide cylinder, and turn on the carbon dioxide supply switch.
- the ethanol (modifier) pump was turned on to start pumping.
- the sample feeding pump was switched on, a sample (20% lactose aqueous solution) was introduced, and crystallization was started.
- the sample feeding pump and the modifier feeding pump were stopped, the knob was closed, and the column was dried by continuing to flow carbon dioxide for 30 minutes or more.
- the carbon dioxide pump was stopped, the main valve of the carbon dioxide cylinder was closed, and the pressure of the knock 'pressure' regulator was gradually reduced. Finally, the exhaust valve was opened, the inside of the container was completely returned to normal temperature and normal pressure, and the crystallized substance in the column was recovered.
- the aerodynamic particle size was measured and the particle shape was observed by SEM on the crystallized product obtained in Example 1 above, and the effect of the operating conditions of the supercritical crystallization apparatus on the particle properties was measured. Was examined.
- the air port sizer body and the attached PC were prepared according to the usage procedure.
- Set dispersion pressure After 4.0 psi, about 0.5 cup of microspar was placed in the sample holder, the lid was closed, and the sample holder was fixed firmly to the mounting part, and the aerodynamic particle diameter was measured.
- a double-sided tape is stuck on the sample table, and the crystallized substance is sprinkled on the double-sided tape.
- the crystallized substance is fixed on the sample table, and Pt-Pd is vapor-deposited using ion sputtering. The shape was confirmed with.
- the basic conditions are as follows: "carbon dioxide flow rate 14.0mLZmin, ethanol flow rate 0.7mLZmin, sample feeding rate 0 • 035mLZmin, pressure 16MPa, temperature 35 ° C, sample concentration (lactose aqueous solution concentration 10% w / w)”
- SEM particle shape
- aerodynamic diameter air sizer
- Table 3 summarizes the yields and aerodynamic diameters of the crystallization products obtained under each of the study conditions.
- the particles observed by the SEM showed similar shapes with similar deviations (FIG. 16). Dramatic change in shape was observed only when the flow rate of carbon dioxide was changed (see FIG. 7).
- the flow rate of carbon dioxide was 6.5 mLZmin or less (ratio of the flow rate of ethanol to the flow rate of carbon dioxide: CZE ⁇ 9.3)
- the shape change of the crystallized product was remarkable.
- the particle size reflects the shape change, the needle-shaped crystals obtained when the flow rate of carbon dioxide is small are crystallized as the flow rate of carbon dioxide increases, with the particle size being as small as about 18 m.
- the product turned into a needle-shaped crystallized mass and the particle size increased to about (see Fig. 7).
- Table 5 summarizes the yields and aerodynamic diameters of the crystallization products obtained under each study condition.
- the change in particle size was not so large as the change in ethanol flow rate, and the change in particle size was in the range of about 514 / zm.
- the change in shape was hardly observed, and the particle size was almost unchanged at around 6-8 IX m.
- Figure 13 shows the relationship of CZE. It was found that the emissive spherical crystallization can be prepared when CZE is 4.
- a crystallization product having a cumulative diameter of 5.2 m was obtained.
- Salbutamol sulfate DPI formulations were prepared and their in vitro inhalation properties evaluated as described below.
- DPI manufactured using commercially available lactose was used as a comparative product. Table 6 shows the results.
- Salbutamol sulfate sieved at 250M and radial globular crystals (Run No. 22 described in Table 5) also sieved at 250M were mixed in a ratio of 3: 7 to obtain the formulation of the present invention.
- This formulation showed good mixing uniformity with a content of 29.2% and an RSD of 3.6% as a result of quantification of 6 measurements.
- a mixture of salbutamol sulfate sieved at 250 M and lactose LH200 (Borculo-Domo), which was also sieved at 250 M, in a ratio of 3: 7 was used.
- Gelatin capsules were filled with 3 mg each of Formulation 1 of the present invention and Comparative Formulation 1.
- Iecheler was used as a device for inhalation. Attach the leveler to the Andersen Cascade Compactor (ACI) via the mouthpiece, and suction for 6 seconds at 40.0 LZmin with the vacuum pump. I pulled. Two sprays (3 mg capsule X 2) were performed per measurement. After the suction, the sample deposited on each of the Stage 0-7, the throat, and the fraction of the device was washed into a volumetric flask with a solvent, and this was used as a sample solution. Salbutamol sulfate in the formulation deposited in each fraction was quantified by the HPLC method, and the rate of reaching the lung relative to the capsule filling amount was determined. The measurement was performed twice for each preparation. Table 6 shows the results.
- a radial spherical crystallized product of the substance was produced as a white powder in the same manner as in Example 1 except that the sample solution was a 20% aqueous solution of salbutamol sulfate.
- the crystallization conditions are as shown in Table 7.
- the radial spherical crystallization product of the present invention obtained by force can be used for various applications.
- One example of such force is the use as a drug such as a DPI preparation. That is, by making the drug into a spherical crystallization product according to the present invention, the drug can be delivered to the alveoli or bronchus at the administration site by means such as inhalation.
- the pharmaceutical carrier a radial spherical crystallization product according to the present invention, a higher drug content, for example, 30% or more, than the conventional DPI carrier is obtained, which is excellent. In vitro inhalation properties can be obtained.
- FIG. 1 is an electron micrograph of a radial spherical crystallized product (lactose).
- FIG. 2 is an electron micrograph of a radial spherical crystallized product (lactose).
- FIG. 3 is a schematic view of a supercritical fluid crystallizer.
- FIG. 4 is a graph showing the effect of ethanol flow rate on particle size and shape change.
- FIG. 5 is a graph showing the effect of pressure on particle size and shape change.
- FIG. 6 is a graph showing the effect of temperature on particle size and shape change.
- FIG. 7 is a graph showing the effect of the flow rate of carbon dioxide on particle size and shape change.
- FIG. 8 is a graph showing the effect of the ratio of the flow rate of ethanol to the flow rate of carbon dioxide (5%) on changes in particle size and shape.
- FIG. 9 is a graph showing the effect of the sample solution flow rate on the particle size and shape change.
- FIG. 10 is a graph showing the effect of pressure on particle size and shape change.
- FIG. 11 is a graph showing the effect of temperature on particle size and shape change.
- FIG. 12 is a graph showing the effect of ethanol flow rate on particle size and shape change.
- FIG. 13 is a schematic diagram showing the relationship between the particle shape of the crystallized product and the ratio (C / E) of the flow rate of ethanol and the flow rate of carbon dioxide.
- FIG. 14 is an electron micrograph of a radial spherical crystallized product (salbutamol sulfate). Explanation of reference numerals
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005506882A JP4622855B2 (ja) | 2003-06-10 | 2004-05-26 | 放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤 |
CA002528413A CA2528413A1 (en) | 2003-06-10 | 2004-05-26 | Radial spherical crystallization product, process for producing the same and dry powder preparation containing the crystallization product |
US10/560,169 US20060275219A1 (en) | 2003-06-10 | 2004-05-26 | Radial spherical crystallization product, process for producing the same, and dry powder preparation containing the crystallization product |
EP04745323A EP1683560A4 (en) | 2003-06-10 | 2004-05-26 | RADIAL SPHERICAL CRYSTALLIZATION PRODUCT, PROCESS FOR PRODUCING THE CRYSTALLIZATION AND PREPARATION OF DRY POWDER CONTAINING THE CRYSTALLIZATION PRODUCT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003165565 | 2003-06-10 | ||
JP2003-165565 | 2003-06-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004110585A1 true WO2004110585A1 (ja) | 2004-12-23 |
WO2004110585A9 WO2004110585A9 (ja) | 2006-03-23 |
Family
ID=33549218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007171 WO2004110585A1 (ja) | 2003-06-10 | 2004-05-26 | 放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060275219A1 (ja) |
EP (1) | EP1683560A4 (ja) |
JP (1) | JP4622855B2 (ja) |
CN (1) | CN1819863A (ja) |
CA (1) | CA2528413A1 (ja) |
WO (1) | WO2004110585A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505605A (ja) * | 2006-10-06 | 2010-02-25 | ニューサウス イノベーションズ ピーティーワイ リミテッド | 粒子の形成 |
WO2010052896A1 (ja) * | 2008-11-04 | 2010-05-14 | 日揮株式会社 | プロピオン酸フルチカゾンを含む局所投与剤 |
US10568837B2 (en) * | 2014-09-11 | 2020-02-25 | Dejan Lamesic | Particles of spherically agglomerated lactose for direct compression and method of preparation thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5544503B2 (ja) * | 2004-05-24 | 2014-07-09 | 独立行政法人物質・材料研究機構 | マリモカーボン及びその製造方法並びにその製造装置 |
US8945598B2 (en) | 2005-12-29 | 2015-02-03 | Cordis Corporation | Low temperature drying methods for forming drug-containing polymeric compositions |
TWI426963B (zh) * | 2011-04-25 | 2014-02-21 | Nat Univ Chung Hsing | Preparation of high purity caffeic acid phenethyl ester micro - nano - powder by supercritical fluid anti - crystallization |
EP3909565A1 (en) * | 2020-05-14 | 2021-11-17 | MEGGLE GmbH & Co. KG | Inhalable lactose containing composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04500925A (ja) * | 1988-10-05 | 1992-02-20 | ファルマシア・アンド・アップジョン・カンパニー | 反溶剤への沈澱を介する微細分化固体結晶性粉末 |
JPH11503448A (ja) * | 1995-04-13 | 1999-03-26 | アストラ・アクチエボラーグ | 吸引可能粒子の製造法 |
JP2002515324A (ja) * | 1998-05-15 | 2002-05-28 | ブラッドフォード パーティクル デザイン パブリック リミティド カンパニー | 粒子製造方法及び装置 |
JP2003010672A (ja) * | 2001-07-03 | 2003-01-14 | Japan Science & Technology Corp | 超臨界媒体中での固体改質方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
EP0277008B1 (en) * | 1987-01-29 | 1995-06-14 | Beecham Group Plc | Process for crystallization of potassium clavulanate |
US5707634A (en) * | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
GB9326574D0 (en) * | 1993-12-31 | 1994-03-02 | King S College London | Dry power inhalers |
GB9413202D0 (en) * | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
SI20305A (sl) * | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristali natrijeve soli pravastatina |
TR200401219T4 (tr) * | 2001-02-26 | 2004-10-21 | Dompe S.P.A. | Mikron ve alt partikül oluşturmak için aparat ve yöntem. |
JP3557588B2 (ja) * | 2001-10-26 | 2004-08-25 | 株式会社東北テクノアーチ | 超・亜臨界流体処理システム及び装置 |
GB0300427D0 (en) * | 2003-01-09 | 2003-02-05 | Univ Strathclyde | Pharmaceutical composition |
-
2004
- 2004-05-26 CN CNA2004800164307A patent/CN1819863A/zh active Pending
- 2004-05-26 EP EP04745323A patent/EP1683560A4/en not_active Withdrawn
- 2004-05-26 WO PCT/JP2004/007171 patent/WO2004110585A1/ja active Application Filing
- 2004-05-26 CA CA002528413A patent/CA2528413A1/en not_active Abandoned
- 2004-05-26 US US10/560,169 patent/US20060275219A1/en not_active Abandoned
- 2004-05-26 JP JP2005506882A patent/JP4622855B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04500925A (ja) * | 1988-10-05 | 1992-02-20 | ファルマシア・アンド・アップジョン・カンパニー | 反溶剤への沈澱を介する微細分化固体結晶性粉末 |
JPH11503448A (ja) * | 1995-04-13 | 1999-03-26 | アストラ・アクチエボラーグ | 吸引可能粒子の製造法 |
JP2002515324A (ja) * | 1998-05-15 | 2002-05-28 | ブラッドフォード パーティクル デザイン パブリック リミティド カンパニー | 粒子製造方法及び装置 |
JP2003010672A (ja) * | 2001-07-03 | 2003-01-14 | Japan Science & Technology Corp | 超臨界媒体中での固体改質方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1683560A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505605A (ja) * | 2006-10-06 | 2010-02-25 | ニューサウス イノベーションズ ピーティーワイ リミテッド | 粒子の形成 |
WO2010052896A1 (ja) * | 2008-11-04 | 2010-05-14 | 日揮株式会社 | プロピオン酸フルチカゾンを含む局所投与剤 |
US10568837B2 (en) * | 2014-09-11 | 2020-02-25 | Dejan Lamesic | Particles of spherically agglomerated lactose for direct compression and method of preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2004110585A9 (ja) | 2006-03-23 |
JPWO2004110585A1 (ja) | 2006-07-20 |
CA2528413A1 (en) | 2004-12-23 |
US20060275219A1 (en) | 2006-12-07 |
JP4622855B2 (ja) | 2011-02-02 |
EP1683560A4 (en) | 2008-10-01 |
CN1819863A (zh) | 2006-08-16 |
EP1683560A1 (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Reverchon et al. | Micronization of antibiotics by supercritical assisted atomization | |
TW492877B (en) | Process for the preparation of respirable particles | |
US6862890B2 (en) | Process for production of nanoparticles and microparticles by spray freezing into liquid | |
JP4728558B2 (ja) | ナノ粒子の製造方法 | |
Kankala et al. | Supercritical fluid (SCF)-assisted fabrication of carrier-free drugs: an eco-friendly welcome to active pharmaceutical ingredients (APIs) | |
US20100092453A1 (en) | Method of producing porous microparticles | |
Li et al. | Inhaled hyaluronic acid microparticles extended pulmonary retention and suppressed systemic exposure of a short-acting bronchodilator | |
Ogienko et al. | Large porous particles for respiratory drug delivery. Glycine-based formulations | |
JP2010528094A (ja) | 表面改質されたエアロゾル粒子、その製造のための方法および装置ならびにこの粒子を含む粉末および分散液 | |
CN108463213A (zh) | 可吸入扎鲁司特颗粒的制备 | |
WO2004110585A1 (ja) | 放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤 | |
Park et al. | Surface modification strategies for high-dose dry powder inhalers | |
Reverchon et al. | Ampicillin micronization by supercritical assisted atomization | |
GB2388541A (en) | Aerosol formulations comprising a particulate active substance suspended in a hydrofluorocarbon | |
JP2008533055A (ja) | 吸入剤 | |
JP2003501378A (ja) | 粒子の被覆方法およびその方法により製造した粒子 | |
JP2003519171A (ja) | 吸入粒子 | |
Zhiyi et al. | Experimental investigation on the micronization of aqueous cefadroxil by supercritical fluid technology | |
Pyo | Two different shapes of insulin microparticles produced by solution enhanced dispersion supercritical fluid (SEDS) process | |
WO2005055978A2 (en) | A method of engineering particles for use in the delivery of drugs via inhalation | |
Kale et al. | Recent advancements in particle engi-neering techniques for pharmaceutical applications | |
CA2477592A1 (en) | Powdery medicinal compositions for inhalation and process for producing the same | |
KR20200014902A (ko) | 비정질 나노구조 제약 물질 | |
RU2504370C1 (ru) | Способ получения высокодисперсных фармацевтических композиций сальбутамола | |
JP6650933B2 (ja) | マトリックス中に分散された活性薬剤ドメインを形成するためのプロセス |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506882 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2528413 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004745323 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006275219 Country of ref document: US Ref document number: 10560169 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048164307 Country of ref document: CN |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 18, CLAIMS, ADDED |
|
WWP | Wipo information: published in national office |
Ref document number: 2004745323 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10560169 Country of ref document: US |